Skip to main content
OpenTrials
Recruiting

NCT Number: NCT02559804

Prospective Study Registry of Peripheral Neuroblastic Tumours Presenting With Spinal Canal Involvement (SCI)

To describe the natural history of peripheral neuroblastic tumour presenting with SCI and evaluate the combined effects of different risk factors on the eventual neurologic and orthopaedic outcomes

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Age range

Up to 18 year

Sex eligibility

All sexes

Study type

Observational

Primary location

About this study

Multi-centre, observational, prospective study registry. About 15% of patients with peripheral neuroblastic tumour present with extradural SCI, of whom approximately 60% are symptomatic. Since SCI may progress to irreversible paraplegia, early diagnosis and prompt treatment is of critical importance.1-3 The treatment options include chemotherapy, neurosurgical decompression and radiation therapy. All may relieve epidural compression, but there is no consensus on which to use first in the individual patient. However, the choice of the treatment could be relevant in the perspective of reducing to the minimum the risk of long-term sequelae.4 Guidelines for the diagnostic work-up and treatment of SCI for International Society of Paediatric Oncology European Neuroblastoma (SIOPEN) neuroblastoma patients were already available in the "guidelines for the treatment of patients with localized resectable neuroblastoma and analysis of prognostic factors" (LNESG1 Protocol), back in 1994,5 although it is unknown how they were applied in the SIOPEN Centres. These guidelines have been reformulated in occasion of the recently activated "European Low and Intermediate risk Neuroblastoma" (LINES Protocol).

There are few publications addressing the diagnosis and treatment of SCI; most are retrospective studies, case reports, or reviews that may be affected by reporting bias.1-9 Therefore new guidelines could be designed based on the information derived from a prospective data collection of newly diagnosed patients.

For this study Spinal Canal Involvement (SCI) is defined when, referring to an axial plane of the spinal cord MRI scan (Figure 1), the tumour extends into the vertebral canal and goes beyond a mentally drown ellipsoid (red circle) passing through the cortical bone of both anterior and posterior arches of the vertebra. This involvement is called "intraspinal" or, better, "intracanal".

Patient data to be collected and included in the corresponding Forms

  • work-up at diagnosis, including radiology report (Computed Tomography or Magnetic Resonance Imaging)
  • treatment administered
  • response to treatment, including radiology report
  • follow-up
  • outcome

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of peripheral neuroblastic tumour - peripheral neuroblastic tumour (neuroblastoma, ganglioneuroblastoma, ganglioneuroma) presenting with SCI, symptomatic or asymptomatic, independent of disease extension (stage), and clinical course (first diagnosis or relapse/progression)
  • No previous chemotherapy, except steroids, in the last 6 months
  • Age <18 years
  • Minimal planned follow-up of 5 years
  • Parent/patient written informed consent (Appendix 1(A,B,C))

Exclusion criteria

  • Invasion of intervertebral foramina only

Treatment and study plan

survival and late effects

Other

survival and late effects

Primary outcomes

  1. prevalence of neurologic consequences

    Time frame: for 5 years

    American Spinal Injury Association ASIA impairment scale

  2. prevalence of orthopedic consequences

    Time frame: for 5 years

    using Common Terminology Criteria for Adverse Events v. 4.0

  3. prevalence of pain

    Time frame: for 5 years

    using Face, Legs, Activity, Cry, Consolability scale (FLACC scale)

Secondary outcomes

  1. relapse or second tumour

    Time frame: 5 years

    event free survival

  2. survival

    Time frame: 5 years

    overall survival

Study contacts

Contact information is provided by the study sponsor or research team.

Riccardo Haupt, MD

CONTACT

[email protected]

01056363462 ext. +39

tiziana landi

CONTACT

[email protected]

051/2144667 ext. +39

Sponsors and collaborators

Lead sponsor

Associazione Italiana Ematologia Oncologia Pediatrica

Other

Collaborators

  • Istituto Giannina Gaslini

Registry information

Acronym: NB-SCI

Important dates

Study start
2014
Primary completion
2029
Study completion
2029
First posted
Sep 24, 2015
Registry last updated
Apr 15, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.